Each of the three antibodies similarly differentiated between the COX-2 positive and negative tumours if either ALG1 or ALG3 were used for the evaluation of the expression of the protein within individual lesions (ALG1: 41.5%-48.8%; ALG3: 46.3%-48.8% of the COX-2 positive lesions). This evidence concerns the gene ALG1 and neoplasm.